It has been demonstrated in different studies that the inhibition of both estrogen receptors (tamoxifen and raloxifene) [44–46] and aromatase pathway (exametasane) [47] reduces contralateral breast cancer relapse. Here, ESR1 is linked to breast carcinoma.